Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | MicrobiomeTrials← Back to trialsNCT07059494
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-03-26Est. Completion: 2027-08-01
Enrollment target: 40 participants Locations- Icahn School of Medicine at Mount Sinai, New York, New York, United States
Other microbiome trials you might be interested in
Chronic HepatitisHepatitis C InfectionHepatocellular Carcinoma
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating pat…
Jacksonville, United StatesEst. completion Mar 4, 2020
Hepatocellular Carcinoma
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial adm…
San Diego, United StatesEst. completion Dec 2027